International Stem Cell Inkomsten in het verleden
Verleden criteriumcontroles 0/6
International Stem Cell has been growing earnings at an average annual rate of 52.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 2.9% per year.
Belangrijke informatie
52.2%
Groei van de winst
53.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -2.9% |
| Rendement op eigen vermogen | -240.8% |
| Nettomarge | -5.6% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe International Stem Cell geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 8 | 0 | 5 | 0 |
| 31 Mar 24 | 8 | 0 | 5 | 0 |
| 31 Dec 23 | 8 | 0 | 5 | 0 |
| 30 Sep 23 | 8 | 0 | 5 | 0 |
| 30 Jun 23 | 8 | 0 | 5 | 0 |
| 31 Mar 23 | 8 | 0 | 5 | 0 |
| 31 Dec 22 | 8 | 0 | 5 | 0 |
| 30 Sep 22 | 8 | -1 | 5 | 0 |
| 30 Jun 22 | 8 | -1 | 5 | 0 |
| 31 Mar 22 | 8 | 0 | 6 | 0 |
| 31 Dec 21 | 7 | -1 | 6 | 0 |
| 30 Sep 21 | 7 | -1 | 6 | 0 |
| 30 Jun 21 | 6 | -2 | 6 | 0 |
| 31 Mar 21 | 6 | -3 | 6 | 0 |
| 31 Dec 20 | 7 | -3 | 7 | 0 |
| 30 Sep 20 | 8 | -5 | 8 | 0 |
| 30 Jun 20 | 9 | -4 | 8 | 0 |
| 31 Mar 20 | 10 | -4 | 9 | 0 |
| 31 Dec 19 | 9 | -4 | 9 | 1 |
| 30 Sep 19 | 9 | -3 | 9 | 1 |
| 30 Jun 19 | 10 | -2 | 9 | 1 |
| 31 Mar 19 | 11 | -2 | 8 | 2 |
| 31 Dec 18 | 11 | -2 | 8 | 2 |
| 30 Sep 18 | 11 | -2 | 7 | 2 |
| 30 Jun 18 | 9 | -5 | 7 | 2 |
| 31 Mar 18 | 8 | -4 | 7 | 2 |
| 31 Dec 17 | 7 | -6 | 7 | 2 |
| 30 Sep 17 | 7 | -3 | 7 | 2 |
| 30 Jun 17 | 7 | 0 | 7 | 2 |
| 31 Mar 17 | 8 | 10 | 7 | 3 |
| 31 Dec 16 | 7 | -1 | 7 | 3 |
| 30 Sep 16 | 7 | -5 | 7 | 2 |
| 30 Jun 16 | 8 | -6 | 7 | 2 |
| 31 Mar 16 | 8 | -16 | 7 | 2 |
| 31 Dec 15 | 8 | -3 | 7 | 2 |
| 30 Sep 15 | 7 | -6 | 7 | 4 |
| 30 Jun 15 | 7 | -7 | 8 | 5 |
| 31 Mar 15 | 7 | -12 | 8 | 6 |
| 31 Dec 14 | 7 | -12 | 8 | 5 |
| 30 Sep 14 | 7 | -11 | 9 | 4 |
| 30 Jun 14 | 7 | -12 | 9 | 4 |
| 31 Mar 14 | 7 | -10 | 9 | 3 |
| 31 Dec 13 | 6 | -10 | 9 | 3 |
Kwaliteitswinsten: ISCO is currently unprofitable.
Groeiende winstmarge: ISCO is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ISCO is unprofitable, but has reduced losses over the past 5 years at a rate of 52.2% per year.
Versnelling van de groei: Unable to compare ISCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ISCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: ISCO has a negative Return on Equity (-240.85%), as it is currently unprofitable.